Jacc publication guides use of caredx's heartcare transplant rejection surveillance in clinical practice

Brisbane, calif.--( business wire )--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the journal of the american college of cardiology (jacc): heart failure has published a detailed guide 1 to help clinicians transition from routine invasive endomyocardial biopsy (emb) to a less invasive acute rejection monitoring protocol in clinical practice.
CDNA Ratings Summary
CDNA Quant Ranking